A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele
- Registration Number
- NCT04135495
- Lead Sponsor
- Eloxx Pharmaceuticals, Inc.
- Brief Summary
This is a Phase 2 open-label, dose-escalation study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele.
In total, up to 16 patients will be enrolled in the trial; up to 4 patients will be homozygotes for G542X, and the remaining patients will be compound heterozygotes with one G542X or phenotypically similar nonsense allele and any Class 1 or Class 2 mutation.
Each patient will receive up to 5 escalating doses as follows:
* ELX-02 0.3 mg/kg per day SC
* ELX-02 0.75 mg/kg per day SC
* ELX-02 1.5 mg/kg per day SC
* An individualized dose of ELX-02, as high as 3.0 mg/kg per day SC, based on the patients observed safety and tolerability, PK at previous doses and the results of laboratory tests.
* ELX-02 1.5 mg/kg per day SC plus 150 mg ivacaftor every 12 bid
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
- Males and females age 18 years and above
- A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X or phenotypically similar nonsense allele, and the second mutation has to be any Class 1 or Class 2 mutation. Patients with one G542X allele or phenotypically similar nonsense allele and a second allele that is not a Class 1 or Class 2 mutation may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor.
- Documented SCC ≥60 mEq
- FEV1 ≥40% predicted normal for age, gender and height at Screening (Knudson Equation)
- Body mass index (BMI) of 19.0 to 30.0 kg/m2 (inclusive). Patients with a lower BMI may be entered into the study at the discretion of the investigator following consultation with the Sponsor.
- Participation in clinical study including administration of any investigational drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study
- History of any organ transplantation
- Major surgery within 180 days (6 months) of Screening
- Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides
- Known allergy to any aminoglycoside
- Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides.
- Dizziness Handicap Inventory (DHI)-H score at screening must be >16.
- Patients receiving CFTR modulators within 2 months of study treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ELX-02 ELX-02 Eukaryotic ribosomal selective glycoside (ERSG) ELX-02 Ivacaftor Eukaryotic ribosomal selective glycoside (ERSG)
- Primary Outcome Measures
Name Time Method AEs associated with different dose levels of ELX-02 From the time of first dosing through the follow-up visit, an average of approximately 9 weeks Area under the plasma concentration curve from time zero to 24 hours (AUC0-24h) Day 1 of treatment periods 1, 2, 3, and 4 Full PK profile 8 blood samples over 24 hours
Peak observed plasma concentration (Cpeak) over time Days 1, 2, and 7 of treatment periods 1-3; Days 1, 2, 7, and 14 of treatment period 4, sparse blood sampling at 30 min and 1 hour post dose Trough observed plasma concentration (Cpredose) over time Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7 and 14 of treatment period 4, sparse sampling at pre-dose Maximum observed plasma concentration (Cmax) on Day 1 Day 1 of treatment periods 1, 2, 3, and 4 Full PK profile 8 blood samples over 24 hours
- Secondary Outcome Measures
Name Time Method Changes from baseline in percent predicted forced expiratory flow at 25-75% (ppFEF25-75) From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 Changes from baseline in percent predicted forced expiratory volume (ppFEV1) From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 Changes from baseline in sweat chloride concentration From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4 Changes from baseline in percent predicted forced vital capacity (ppFVC) From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4
Trial Locations
- Locations (10)
Boston Children's Hospital
🇺🇸Boston, Massachusetts, United States
Stanford School of Medicine
🇺🇸Palo Alto, California, United States
National Jewish Health
🇺🇸Denver, Colorado, United States
Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Nationwide Children's Hospital
🇺🇸Columbus, Ohio, United States
The University of Montreal Health Centre
🇨🇦Montreal, Quebec, Canada
Foothills Hospital Calgary (University of Calgary)
🇨🇦Calgary, Alberta, Canada
St. Michael's Hospital
🇨🇦Toronto, Ontario, Canada
Long Beach Memorial
🇺🇸Long Beach, California, United States
Baylor College of Medicine
🇺🇸Houston, Texas, United States